Innovative Approaches & Ongoing Studies Will Increase the Efficacy of Cardiac Biomarkers


New biomarker protocols and the use in treatment of other conditions than cardiovascular diseases are expected to drive growth in the cardiac biomarkers industry.

Obtaining rapid results through cardiac biomarkers is a novel approach of cardiologists to diagnose and treat cardiac diseases. Monitoring heart conditions has become easier than before in case of acute coronary syndrome (ACS), include myocardial infraction, congestive heart failure, and other cardiovascular diseases (CVDs). The cost effectiveness as well as the ability of these devices to detect accurate and rapid protection of heart failures are responsible for growing prominence across the world.

Cardiac Biomarkers

In addition, technological advancement and rising popularity of point of care testing have increased its demand. Researchers and scientists are endeavoring to find new applications and conducting tests to determine ability and introduce new approaches. Development of high sensitive biomarkers for risk stratification is impacting the global industry. In its recent report on the cardiac biomarkers market, Allied Market Research states that the market is expected to garner a revenue of $2,085.9 million by 2020 and grow at a CAGR of 18.9% from 2015 to 2020.

Researchers to lay a foundation for use of Cardiac Biomarkers for prediction of other conditions:

Researchers are testing new efficacy of cardiac biomarkers for different conditions to widen the applications of these devices. Japanese researchers are conducting a study to test cardiac biomarkers for prediction of outcomes in chronic kidney disease in type 2 diabetic patients. Based on their study, they have found that NT-proBNP, a cardiac biomarker may predict the outcomes of chronic kidney diseases.

Kumiko Hamano, MD, from Kanto Rosai Hospital in Kawasaki, Japan, and colleagues studies total 109 patients with diabetes, of which 14 patients who suffered cardiovascular events had probability of having NT-proBNP levels above 153 pg/ml. In addition, probability of having NT-proBNP levels was above 120 pg/ml in another 14 patients who experienced decrease in estimated glomerular filtration rate (eGFR) or reached the renal endpoint of a 30% or more. The odds ratio was counted for both condition in orders to predict renal and cardiovascular outcomes. They found that odds ratio for NT-proBNP level at or above 120 pg/mL was 5.4, whereas, for levels at or above 153 pg/ml was 9.8.

“It is possible to stratify diabetic patients by simple measurement of NT-proBNP, which is reproducible and inexpensive and enables cardiovascular disease prevention and chronic kidney disease prevention as well,” said Hamano and colleagues as per Medpage Today. They are conducting more studies to confirm results to determine accurate cutoff values. As per the cardiorenal syndrome, chronic kidney disease progression is accelerated by cardiovascular disease, while, cardiovascular disease is amplified by chronic kidney disease itself.

So Hamano and colleague conducted the study with an aim to determine whether NT-proBNP can be used for prediction of both cardiac and kidney diseases. In the study, they have also found that gender made no difference in the outcomes. They concluded that the NT-proBNP can be used as a biomarker for kidney disease as it is a cardiac screening tool having good sample stability.

Though there is a scope of improvement and more tests to be conducted, the positive results will mark as a significant step in application of cardiac biomarkers. Researchers across the world are laying a foundation through tests and studies to widen the application of these devices for other related diseases related to cardiac conditions. This study also marks a significant step in advancement of the cardiac biomarkers industry worldwide.

New cardiac biomarker protocols to provide early diagnosis to patients:

Technological advancements in the cardiac biomarkers are focused on increasing accuracy and efficacy in various conditions. This will lead to early diagnosis of a disease and shorten the time of recovery of patients. In addition, there is a growing prevalence of cardiovascular diseases that encourages researcher to develop novel approaches for diagnosis and treatment.

Scientists believe that the development of sensitive and accurate assays for cardiac biomarkers would help in earlier detection of myocardial infraction. This has enabled the timing of second biomarker sampling from six hours to three hours after first sampling is conducted. There are other studies which have tested biomarker protocols for a very short duration, for instance one hour to rule in or rule out myocardial injury in patients with chest pain. The efficacy and usefulness of these protocols were tested by Dr. Anne Vorlat and team with a primary aim to develop an early presenter model to discover ischemia-induced myocardial injury.

Anne Vorlat, MD, Antwerp University Hospital, Department of Cardiology, Edegem, Belgium, tested this early presenter model on 107 stable patients by stenting of a significant coronary artery stenosis that induced myocardial ischemia. They confirmed their hypothesis that myonecrosis in early presenters was underestimated by short biomarkers protocols.

There is a growing need for fast track biomarker protocol to shorten the delay between diagnosis and treatment of chronic coronary syndromes. Dr. Vorlat also believes that the increase in demand for point of care testing in an emergency department will encourage this early presenter model in hospitals. She also emphasized on the need to provide accurate knowledge about short cardiac biomarker protocols to detect ischemia induced myocardial injury in early presenters.

The research and development activities across institutes and laboratories in the world are focused on development of accurate and specific biomarkers for early detections of myocardial injury. The developments that are focused on increasing the accuracy of prediction of cardiovascular diseases present growth opportunities in the global cardiac biomarkers market.

Author Bio:

Pratik KirvePratik Kirve is a content writer at Allied Market Research Market Research. He has avid interest in studying changing dynamics for advanced healthcare technologies. When he is not articulating corporate insights, he spends his time reading, observing, and analyzing market behavior.

Leave A Reply

Your email address will not be published.